ASCO Conference, page-26

Hi @QiQi & All,

Great news, it’s all progress, just reading through all now & have to have a closer look at poster presentation.

I also saw that article you posted regarding Keynote 062 gastric cancer trial with Keytruda & Josep Tabernero as lead investigator who I believe was also presenting at ASCO from memory. If you read his disclosures he is on quite a few advisory medical boards including IMU, I totally agree, he has his finger on the pulse of new cancer developments, especially in biologicals as what we are doing in a completely new area of B cell vaccines in multiple indications. He’s not the only one involved with IMU lately, I don’t think it’s a matter of “sticking your nose in the trough”, typical ASX speak...

We had discussed the outcome of Keynote 062 Gastric Ca trial results with what was available recently, but this is seen to not be all a negative, looking at patients that may be not be able to tolerate chemo, & Keytruda alone could possibly be of benefit to patients who may not be able to tolerate chemo. I’m so sorry, had no time to post or even read ANNs lately, but have been reading Pharma news early in the am over coffee b4 work & an unrelated article to IMU on ASCO did catch my eye:

https://www.fiercepharma.com/marketing/asco-non-clinical-topics-real-world-data-competition-and-differentiation-analyst


Here we are looking at a possibly ‘overcrowded’ space in
Cancer Immunotherapy biotechs....what stands out? IMU are targeting a different cell type in our immune system than T cells such as Keytruda, they create ‘memory cells’ to attack what they are specifically targeting. Is it safer & provide patients with more longevity than Keytruda? Will patients have the opportunity to have combo treatment if chemo is not the answer?

Well the lead investigator from Keytruda Keynote 620 trial is on our advisory board, so as a major International specialist in this field of medicine, & a respected member of the Cancer Medical community, I feel very comfortable with this. Now back to reading the poster presentation in detail. Also guys & gals, check the trial site, looks like we have picked up a few in India. . Best wishes